Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>DexCom Inc.'s latest financial performance for the third quarter of 2025 revealed a mixture of strengths and challenges, reflected in both strategic updates and financial metrics.</li><li>The company reported a 22% increase in worldwide revenue, reaching $1.21 billion compared to $994 million in the same quarter last year.</li><li>This growth was driven by strong performance in both the U.S. and international markets, particularly due to expanded continuous glucose monitoring (CGM) access and the broadening of their customer base across the type 2 diabetes population.</li></ul>

DexCom Inc.'s latest financial performance for the third quarter of 2025 revealed a mixture of strengths and challenges, reflected in both strategic updates and financial metrics.The company reported a 22% increase in worldwide revenue, reaching $1.21 billion compared to $994 million in the same quarter last year.This growth was driven by strong performance in both the U.S. and international markets, particularly due to expanded continuous glucose monitoring (CGM) access and the broadening of their customer base across the type 2 diabetes population.

Dexcom’s Game-Changing Strategy: Is the Type 2 Diabetes Market Its Next Goldmine?

<ul><li>DexCom Inc., a leader in continuous glucose monitoring (CGM) systems, reported significant developments in its second quarter of 2025 earnings call.</li><li>Highlighting a strong quarter, DexCom achieved a 15% organic revenue growth from the previous year, totaling $1.16 billion.</li><li>This growth was predominantly driven by increased demand for CGM in both the U.S. and international markets, coupled with expanded coverage for type 2 non-insulin diabetes patients.</li></ul>

DexCom Inc., a leader in continuous glucose monitoring (CGM) systems, reported significant developments in its second quarter of 2025 earnings call.Highlighting a strong quarter, DexCom achieved a 15% organic revenue growth from the previous year, totaling $1.16 billion.This growth was predominantly driven by increased demand for CGM in both the U.S. and international markets, coupled with expanded coverage for type 2 non-insulin diabetes patients.

DexCom’s Market Expansion Move: Will Targeting Non-Insulin Users Pay Off?

<ul><li>DexCom’s latest earnings and strategy pivot have reignited investor attention as the company recalibrates its focus on the vast, underpenetrated Type 2 diabetes market.</li><li>After suffering a 41% stock drop in July 2024 due to poor execution in its transition away from its traditional Type 1 diabetes stronghold, the company now appears to be correcting course—not by retreating, but by accelerating into the same direction with more refined tactics.</li><li>The first quarter of 2025 showed encouraging signs, including record-breaking new patient additions, expanded insurance coverage from all three major PBMs for non-insulin-dependent patients, and the introduction of Stelo, DexCom’s first over-the-counter CGM.</li></ul>

DexCom’s latest earnings and strategy pivot have reignited investor attention as the company recalibrates its focus on the vast, underpenetrated Type 2 diabetes market.After suffering a 41% stock drop in July 2024 due to poor execution in its transition away from its traditional Type 1 diabetes stronghold, the company now appears to be correcting course—not by retreating, but by accelerating into the same direction with more refined tactics.The first quarter of 2025 showed encouraging signs, including record-breaking new patient additions, expanded insurance coverage from all three major PBMs for non-insulin-dependent patients, and the introduction of Stelo, DexCom’s first over-the-counter CGM.

DexCom Eyes Explosive Growth with Game-Changing Type 2 Strategy—Is This Its Biggest Pivot Yet?

<ul><li>DexCom, Inc. reported its first-quarter 2025 earnings, demonstrating a commendable 14% organic revenue growth from the previous year.</li><li>The U.S. market drove much of this growth, achieving a 15% increase in revenue, fueled by robust demand and broader access to their continuous glucose monitoring (CGM) systems.</li><li>DexCom's strategic focus on expanding their prescriber base and enhancing commercial reach has begun to manifest in increased customer acquisition, particularly in the type 2 diabetes sector, where their coverage has expanded significantly.</li></ul>

DexCom, Inc. reported its first-quarter 2025 earnings, demonstrating a commendable 14% organic revenue growth from the previous year.The U.S. market drove much of this growth, achieving a 15% increase in revenue, fueled by robust demand and broader access to their continuous glucose monitoring (CGM) systems.DexCom's strategic focus on expanding their prescriber base and enhancing commercial reach has begun to manifest in increased customer acquisition, particularly in the type 2 diabetes sector, where their coverage has expanded significantly.

DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move?

<ul><li>DexCom Inc.'s latest earnings for the fourth quarter of 2024 reports a period of strategic growth and investment, aligning with the company's guidance and expectations.</li><li>The company achieved an 8% organic revenue growth in the fourth quarter year-over-year, with full-year organic growth at 12%.</li><li>An increase in the customer base by approximately 25% to over 2.8 million globally was a critical driver of this growth.</li></ul>

DexCom Inc.'s latest earnings for the fourth quarter of 2024 reports a period of strategic growth and investment, aligning with the company's guidance and expectations.The company achieved an 8% organic revenue growth in the fourth quarter year-over-year, with full-year organic growth at 12%.An increase in the customer base by approximately 25% to over 2.8 million globally was a critical driver of this growth.

Dexcom Inc.: Will Sensor Tech Advancements Solidify Its Lead In Continuous Glucose Monitoring?

United States

DexCom Inc. is a medical device company focused on the design and development of continuous glucose monitoring systems for people with diabetes.  The Company has developed a small implantable device that continuously measures glucose levels in subcutaneous tissue just under the skin, and a small external receiver to which the sensor transmits glucose levels at specified intervals.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dexcom Inc (DXCM US)

Dexcom’s Game-Changing Strategy: Is the Type 2 Diabetes Market Its Next Goldmine?

DexCom Inc.'s latest financial performance for the third quarter of 2025 revealed a mixture of strengths and challenges, reflected in both...

Baptista Research

DexCom’s Market Expansion Move: Will Targeting Non-Insulin Users Pay Off?

DexCom Inc., a leader in continuous glucose monitoring (CGM) systems, reported significant developments in its second quarter of 2025 earnings...

Baptista Research

DexCom Eyes Explosive Growth with Game-Changing Type 2 Strategy—Is This Its Biggest Pivot Yet?

DexCom’s latest earnings and strategy pivot have reignited investor attention as the company recalibrates its focus on the vast, underpenetrated...

Baptista Research

DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move?

DexCom, Inc. reported its first-quarter 2025 earnings, demonstrating a commendable 14% organic revenue growth from the previous year. The U.S....

Baptista Research

Dexcom Inc.: Will Sensor Tech Advancements Solidify Its Lead In Continuous Glucose Monitoring?

DexCom Inc.'s latest earnings for the fourth quarter of 2024 reports a period of strategic growth and investment, aligning with the company's...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)